Table I.
Baseline Patient Demographics and Clinical Characteristics
| Patients, n (%)
|
||
|---|---|---|
| Characteristic | FND→R N = 78 |
RFND N = 80 |
| Age, years; median range | 54 24-76 |
55 20-76 |
| Sex, female | 51 (65) | 34 (43) |
| Diagnosis | ||
| FL | 56 (72) | 55 (69) |
| MZL | 6 (8) | 12 (15) |
| SLL | 16 (20) | 13 (16) |
| B symptoms, yes | 7 (9) | 11 (14) |
| Bone marrow involvement | 72 (92) | 71 (89) |
| FLIPI Score, | ||
| low (0-1) | 15 (19) | 17 (21) |
| intermediate (2) | 34 (44) | 39 (49) |
| high (≥ 3) | 29 (37) | 24 (30) |
| Low tumour burden | 23 (30) | 25 (31) |
| Bulky cut-off? | 4 (5) | 7 (9) |
FL, follicular lymphoma; FLIPI, Follicular Lymphoma International Prognostic Index; FND→R, sequential fludarabine, mitoxantrone, dexamethasone followed by rituximab; MZL, marginal zone lymphoma; RFND, concurrent fludarabine, mitoxantrone, dexamethasone and rituximab; SLL, small lymphocytic lymphoma.